CANNABIS Derivative (Sativex®)

Clinical Indication

Multiple sclerosis

Comments

see East Midlands policy

The BMA cancard statement can be found here

Date of classification

June 2015

Do not prescribe

Drugs not recommended for use in LLR because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety